The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/23/2019 |
| Start Date: | November 1, 2009 |
| End Date: | January 2020 |
The purpose of this study is to evaluate the level of a specific protein (PTEN) in the cancer
cells of chronic myelomonocytic leukemia (CMML) patients. This protein might be involved in
the transformation from normal blood cells to leukemia cells. The PTEN protein has not been
investigated in CMML specifically but it has been discovered in closely related cancers. If
this study demonstrates an abnormality in this protein, future testing will be designed to
evaluate the genetic abnormality that resulted in lack of the normal presence of this
protein. The goal is that the results of this study will help to develop new drugs and
strategies to treat the future patients with CMML by understanding the abnormality of the
disease at the cellular and molecular levels. The results of this study can also be utilized
by future studies to develop individualized treatment to patients who have abnormal levels of
this protein.
cells of chronic myelomonocytic leukemia (CMML) patients. This protein might be involved in
the transformation from normal blood cells to leukemia cells. The PTEN protein has not been
investigated in CMML specifically but it has been discovered in closely related cancers. If
this study demonstrates an abnormality in this protein, future testing will be designed to
evaluate the genetic abnormality that resulted in lack of the normal presence of this
protein. The goal is that the results of this study will help to develop new drugs and
strategies to treat the future patients with CMML by understanding the abnormality of the
disease at the cellular and molecular levels. The results of this study can also be utilized
by future studies to develop individualized treatment to patients who have abnormal levels of
this protein.
Inclusion Criteria:
- Subject must be at least 18 years or older.
- Subject must sign informed consent.
- For study population only, the subject must have a CMML diagnosis based on the WHO
2009 criteria.
- For control population only, the subject must be deemed healthy with no hematologic
disorders.
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Peter Emanuel, MD
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
